Free Newsletter
Pfizer top R&D spender worldwide
Hey, big spenders: Pfizer shelled out more on R&D last year than any other company in the world, and drug makers in general have stepped up their research budgets, the European Commission says. Not surprising, considering the leaks in Big Pharma pipelines--and looming threat of blockbusters going off-patent.
Pfizer spent $8.18 billion, elbowing Ford out of the top slot. Johnson & Johnson came in third. Merck boosted its spending by 24 percent, AstraZeneca by 15 percent; J&J by 13 percent; and GlaxoSmithKline by 10 percent. The question is whether the outlay will do much good.
- see the EU's press release
- read the AP report article
ALSO: Pfizer announced that it has hired a new R&D chief and launched a biotech center. Report
Related Articles:
Where's the ROI on drug R&D budgets? Report
Pfizer's future rests with biotech. Report
Pfizer to invest $50M in biotech start-ups. Report
Pfizer goes public with R&D pipeline. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





